<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424189</url>
  </required_header>
  <id_info>
    <org_study_id>C-09-036</org_study_id>
    <nct_id>NCT01424189</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)</brief_title>
  <official_title>Clinical Investigation of AcrySof® IQ ReSTOR® Multifocal Toric Intraocular Lens Models SND1T3/ SND1T4/ SND1T5/ SND1T6</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of an investigational
      multifocal toric intraocular lens (IOL) compared to an FDA-approved multifocal IOL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants 21 years and older within the targeted astigmatism range and in need of cataract
      extraction in both eyes were consented and randomized in a 2:1 ratio at each investigative
      site to receive either the AcrySof® IQ ReSTOR® Multifocal Toric IOL or the control AcrySof®
      ReSTOR® Multifocal IOL in both eyes. Each participant completed a preoperative examination of
      both eyes, implantation of the IOL at the operative visit for each eye, and up to 8
      postoperative visits, with monocular testing at Day 1-2, Day 7-14, and Day 30-60 and
      binocular testing at Day 120-180 and Day 340-420/Visit 5 following the second implantation.
      The eye with the greater amount of astigmatism was implanted first (first operative eye). The
      second eye implant was intended to occur within 30 days after the first eye implant but not
      prior to 7 days after the first eye implant. Both eyes needed to qualify under
      inclusion/exclusion criteria at the preoperative visit. If the first eye was excluded during
      surgery, the second eye was not eligible. If the second eye was excluded during surgery, only
      the first eye was followed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Monocular Uncorrected Distance Visual Acuity (UCDVA) at Fixed Distance at Visit 5</measure>
    <time_frame>Month 12 from second eye implantation</time_frame>
    <description>Visual acuity (VA) was measured monocularly (each eye separately) without visual correction using a 100% contrast ETDRS (Early Treatment of Diabetic Retinopathy Study) chart positioned 4 meters (m) from the participant under well-lit conditions. +0.25 diopter (D) spherical power was applied to correct for optical infinity. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Monocular Uncorrected Near Visual Acuity (UCNVA) at Fixed Distance at Visit 5</measure>
    <time_frame>Month 12 from second eye implantation</time_frame>
    <description>VA was measured monocularly without visual correction using a hand-held ETDRS chart at a fixed distance that differed by lens model implanted. The logMAR ETDRS near visual acuity chart was designed for use at 40 cm; results obtained at other distances were converted to reflect the change in apparent letter size that results from the change in distance. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5</measure>
    <time_frame>Month 12 from second eye implantation</time_frame>
    <description>The rate of actual and potential secondary surgical interventions (SSIs) related to the optical properties of the IOL was estimated. If an ocular surgical intervention was performed, it qualified as an actual SSI; however; if the participant met the protocol-specified criteria that would warrant an SSI, but didn't actually undergo the SSI, it qualified as a potential SSI. Rate is presented as percentage of participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena &amp; Lens EffectS (APPLES) Questionnaire at Visit 5</measure>
    <time_frame>Month 12 from second eye implantation</time_frame>
    <description>Visual disturbances/distortions were reported by the participant on the Assessment of Photic Phenomena and Lens EffectS (APPLES) questionnaire, a Patient Reported Outcome (PRO) questionnaire intended to evaluate 10 distinct visual phenomena associated with cataract extraction and IOL implantation. The first 20 questions addressed both the frequency and severity of the phenomena using a 4-point categorical scale ranging from &quot;never&quot; to &quot;always&quot; (frequency) or &quot;none&quot; to &quot;severe&quot; (severity). The final (21st) question indicated whether the participant answered the questions based on experiences with or without glasses. The participant completed the assessment as a retrospective analysis of the previous week. Rate is presented as the percentage of participants with severity score &quot;severe&quot; for the visual phenomenon.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">677</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>ReSTOR Toric IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ReSTOR IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL</intervention_name>
    <description>Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient</description>
    <arm_group_label>ReSTOR Toric IOL</arm_group_label>
    <other_name>Models SND1T3, SND1T4, SND1T5, SND1T6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof® ReSTOR® Multifocal IOL Model SA60D3</intervention_name>
    <description>Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient</description>
    <arm_group_label>ReSTOR IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with bilateral cataracts;

          -  Able to comprehend and sign a statement of informed consent;

          -  Calculated lens power and astigmatism within the available range;

          -  Willing and able to complete all required postoperative visits;

          -  Planned cataract removal by phacoemulsification;

          -  Potential postoperative visual acuity of 0.2 logMAR or better in both eyes;

          -  Preoperative astigmatism in both operative eyes as described in the clinical protocol;
             Note: Corneal incisions made to reduce astigmatism will not be allowed during the
             course of the study.

          -  Clear intraocular media other than cataract in study eyes;

          -  Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR in
             each eye;

          -  Pupil size greater than or equal to 6 mm after dilation;

          -  Able to undergo second eye surgery within 30 days of the first eye surgery;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Significant irregular corneal aberration as demonstrated by corneal topography;

          -  Keratopathy/Kerectasia - any corneal abnormality, other than regular corneal
             astigmatism;

          -  Any inflammation or edema (swelling) of the cornea;

          -  Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal
             disorders) that are predicted (by subjective assessment of the retina) to cause future
             acuity losses to a level worse than 0.2 logMAR;

          -  Reasonably expected to require a secondary surgical intervention at any time during
             the study (other than YAG capsulotomy);

          -  Previous corneal refractive surgery;

          -  Amblyopia;

          -  Clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial
             dystrophy);

          -  Diabetic retinopathy;

          -  Extremely shallow anterior chamber, not due to swollen cataract;

          -  Microphthalmos;

          -  Previous retinal detachment;

          -  Previous corneal transplant;

          -  Recurrent severe anterior or posterior segment inflammation of unknown etiology;

          -  Rubella or traumatic cataract;

          -  Iris neovascularization;

          -  Glaucoma (uncontrolled or controlled with medication);

          -  Aniridia;

          -  Optic nerve atrophy;

          -  Pregnancy;

          -  Current participation in another investigational drug or device study that may
             confound the results of this investigation;

          -  Other planned ocular surgery procedures, including, but not limited to LASIK,
             astigmatic keratotomy and limbal relaxing incisions, for the duration of the study;

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Expert Clinical Project Lead, GCRA, Surgical</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <results_first_submitted>January 13, 2017</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract surgery</keyword>
  <keyword>Intraocular lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 21 investigative sites located in the United States.</recruitment_details>
      <pre_assignment_details>Of the 677 participants enrolled, 103 were exited prior to randomization as screen failures. This reporting population includes all participants with successful IOL implantation in at least 1 eye (574).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ReSTOR Toric IOL</title>
          <description>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation</description>
        </group>
        <group group_id="P2">
          <title>ReSTOR IOL</title>
          <description>AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="386"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="373"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all participants with successful IOL implantation in at least 1 eye.</population>
      <group_list>
        <group group_id="B1">
          <title>ReSTOR Toric IOL</title>
          <description>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation</description>
        </group>
        <group group_id="B2">
          <title>ReSTOR IOL</title>
          <description>AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="386"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="574"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.91" spread="9.20"/>
                    <measurement group_id="B2" value="68.36" spread="8.13"/>
                    <measurement group_id="B3" value="67.38" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="376"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Monocular Uncorrected Distance Visual Acuity (UCDVA) at Fixed Distance at Visit 5</title>
        <description>Visual acuity (VA) was measured monocularly (each eye separately) without visual correction using a 100% contrast ETDRS (Early Treatment of Diabetic Retinopathy Study) chart positioned 4 meters (m) from the participant under well-lit conditions. +0.25 diopter (D) spherical power was applied to correct for optical infinity. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.</description>
        <time_frame>Month 12 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with successful IOL implantation in the first implanted eye with data at visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ReSTOR Toric IOL</title>
            <description>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism</description>
          </group>
          <group group_id="O2">
            <title>ReSTOR IOL</title>
            <description>AcrySof® ReSTOR® Multifocal IOL Model SA60D3</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Monocular Uncorrected Distance Visual Acuity (UCDVA) at Fixed Distance at Visit 5</title>
          <description>Visual acuity (VA) was measured monocularly (each eye separately) without visual correction using a 100% contrast ETDRS (Early Treatment of Diabetic Retinopathy Study) chart positioned 4 meters (m) from the participant under well-lit conditions. +0.25 diopter (D) spherical power was applied to correct for optical infinity. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.</description>
          <population>This analysis population includes all participants with successful IOL implantation in the first implanted eye with data at visit.</population>
          <units>logMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.126" spread="0.013"/>
                    <measurement group_id="O2" value="0.125" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>With 300 subjects in the ReSTOR Toric IOL test group and 150 subjects in the ReSTOR IOL control group, there was over 99% power to demonstrate that the upper 95% confidence limit for the observed difference in UCDVA between IOL groups was less than the clinical performance target of 0.1 logMAR units at Month 12, assuming the true difference between groups is zero. This was based on an assumed standard deviation for UCDVA of 0.16 logMAR units and a 1-sided, α=0.05 test.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.030</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Monocular Uncorrected Near Visual Acuity (UCNVA) at Fixed Distance at Visit 5</title>
        <description>VA was measured monocularly without visual correction using a hand-held ETDRS chart at a fixed distance that differed by lens model implanted. The logMAR ETDRS near visual acuity chart was designed for use at 40 cm; results obtained at other distances were converted to reflect the change in apparent letter size that results from the change in distance. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.</description>
        <time_frame>Month 12 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with successful IOL implantation in the first implanted eye with data at visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ReSTOR Toric IOL</title>
            <description>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism</description>
          </group>
          <group group_id="O2">
            <title>ReSTOR IOL</title>
            <description>AcrySof® ReSTOR® Multifocal IOL Model SA60D3</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Monocular Uncorrected Near Visual Acuity (UCNVA) at Fixed Distance at Visit 5</title>
          <description>VA was measured monocularly without visual correction using a hand-held ETDRS chart at a fixed distance that differed by lens model implanted. The logMAR ETDRS near visual acuity chart was designed for use at 40 cm; results obtained at other distances were converted to reflect the change in apparent letter size that results from the change in distance. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.</description>
          <population>This analysis population includes all participants with successful IOL implantation in the first implanted eye with data at visit.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.015"/>
                    <measurement group_id="O2" value="0.24" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>With 300 subjects in the ReSTOR Toric IOL test group and 150 subjects in the ReSTOR IOL control group, there was over 99% power to demonstrate that the upper 95% confidence limit for the observed difference in UCNVA between IOL groups was less than the clinical performance target of 0.1 logMAR units at Month 12, assuming the true difference between groups is zero. This estimate was based on an assumed standard deviation for UCNVA of 0.16 logMAR units and a 1-sided, α=0.05 test.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>-0.017</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5</title>
        <description>The rate of actual and potential secondary surgical interventions (SSIs) related to the optical properties of the IOL was estimated. If an ocular surgical intervention was performed, it qualified as an actual SSI; however; if the participant met the protocol-specified criteria that would warrant an SSI, but didn’t actually undergo the SSI, it qualified as a potential SSI. Rate is presented as percentage of participants.</description>
        <time_frame>Month 12 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with attempted IOL implantation (successful or aborted after contact with the eye). For participants with actual SSIs, performance testing outcomes conducted prior to the secondary intervention were carried forward to the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ReSTOR Toric IOL</title>
            <description>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism</description>
          </group>
          <group group_id="O2">
            <title>ReSTOR IOL</title>
            <description>AcrySof® ReSTOR® Multifocal IOL Model SA60D3</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5</title>
          <description>The rate of actual and potential secondary surgical interventions (SSIs) related to the optical properties of the IOL was estimated. If an ocular surgical intervention was performed, it qualified as an actual SSI; however; if the participant met the protocol-specified criteria that would warrant an SSI, but didn’t actually undergo the SSI, it qualified as a potential SSI. Rate is presented as percentage of participants.</description>
          <population>This analysis population includes all participants with attempted IOL implantation (successful or aborted after contact with the eye). For participants with actual SSIs, performance testing outcomes conducted prior to the secondary intervention were carried forward to the final analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Implanted Eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="386"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04"/>
                    <measurement group_id="O2" value="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Implanted Eye</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="383"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52"/>
                    <measurement group_id="O2" value="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena &amp; Lens EffectS (APPLES) Questionnaire at Visit 5</title>
        <description>Visual disturbances/distortions were reported by the participant on the Assessment of Photic Phenomena and Lens EffectS (APPLES) questionnaire, a Patient Reported Outcome (PRO) questionnaire intended to evaluate 10 distinct visual phenomena associated with cataract extraction and IOL implantation. The first 20 questions addressed both the frequency and severity of the phenomena using a 4-point categorical scale ranging from &quot;never” to “always” (frequency) or “none” to “severe” (severity). The final (21st) question indicated whether the participant answered the questions based on experiences with or without glasses. The participant completed the assessment as a retrospective analysis of the previous week. Rate is presented as the percentage of participants with severity score &quot;severe&quot; for the visual phenomenon.</description>
        <time_frame>Month 12 from second eye implantation</time_frame>
        <population>This analysis population includes all participants with attempted IOL implantation (successful or aborted after contact with the eye).</population>
        <group_list>
          <group group_id="O1">
            <title>ReSTOR Toric IOL</title>
            <description>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism</description>
          </group>
          <group group_id="O2">
            <title>ReSTOR IOL</title>
            <description>AcrySof® ReSTOR® Multifocal IOL Model SA60D3</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena &amp; Lens EffectS (APPLES) Questionnaire at Visit 5</title>
          <description>Visual disturbances/distortions were reported by the participant on the Assessment of Photic Phenomena and Lens EffectS (APPLES) questionnaire, a Patient Reported Outcome (PRO) questionnaire intended to evaluate 10 distinct visual phenomena associated with cataract extraction and IOL implantation. The first 20 questions addressed both the frequency and severity of the phenomena using a 4-point categorical scale ranging from &quot;never” to “always” (frequency) or “none” to “severe” (severity). The final (21st) question indicated whether the participant answered the questions based on experiences with or without glasses. The participant completed the assessment as a retrospective analysis of the previous week. Rate is presented as the percentage of participants with severity score &quot;severe&quot; for the visual phenomenon.</description>
          <population>This analysis population includes all participants with attempted IOL implantation (successful or aborted after contact with the eye).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blurred vision</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Color distortion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flat lines look curved</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Straight lines look tilted</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double vision</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling sick due to visual distortion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glare</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Halos</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hazy vision</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Starbursts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This analysis group includes all participants with attempted IOL implantation (successful or aborted after contact with the eye).</time_frame>
      <desc>An Adverse Event (AE) was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical sign, whether or not related to the investigational device. AEs were collected as solicited comments and as observations by the Investigator as outlined in the protocol. &quot;At Risk&quot; population for ocular AEs is included with unit of &quot;eyes.&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>ReSTOR Toric IOL</title>
          <description>AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism</description>
        </group>
        <group group_id="E2">
          <title>ReSTOR IOL</title>
          <description>AcrySof® ReSTOR® Multifocal IOL Model SA60D3</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Eye disorder (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Eye disorder (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Glare (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Glare (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Halo vision (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Halo vision (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Iris atrophy (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Iris atrophy (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Macular hole (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Macular oedema (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Photopsia (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Photopsia (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Retinal detachment (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Retinal detachment (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Retinal tear (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vision blurred (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vision blurred (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Visual impairment (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Visual impairment (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vitreous prolapse (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Device dislocation (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cataract operation complication (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Cataract operation complication (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Eye injury (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Surgical procedure repeated (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Surgical procedure repeated (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Wound complication (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Corneal operation (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Corneal operation (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Eye laser surgery (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Eye laser surgery (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Intraocular injection (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Intraocular lens repositioning (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Keratometry (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Keratomileusis (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Keratomileusis (Second Implanted Eye) A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Retinal operation (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Retinopexy (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Retinopexy (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Suture insertion (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Vitrectomy (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification (First Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification (Second Implanted Eye)</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Expert Clinical Project Lead, GCRA, Surgical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

